HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

UK Notes PPI Dermatosis Risk: Will FDA Make Similar Communication?

This article was originally published in The Tan Sheet

Executive Summary

The UK drug regulator announces “a very low risk” of sub-acute cutaneous lupus erythematosus from use of PPIs, which are available there with the same ingredients approved for use in the US in products available OTC and RX – esomeprazole, lansoprazole and omeprazole – and Rx only, pantoprazole and rabeprazole.

Advertisement

Related Content

UK Nexium Ad Rapped For Downplaying Treatment For Persistent Heartburn
Zegerid OTC, Private Label Omeprazole Add Drug Interaction Warnings
Public Citizen Urges FDA To Add Sweeping Warnings To PPI Labels

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

RS123405

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel